Stockreport

Novartis exit from fevipiprant pressures Gossamer Bio, down 38% premarket [Seeking Alpha]

Gossamer Bio, Inc.  (GOSS) 
Last gossamer bio, inc. earnings: 3/24 07:00 am Check Earnings Report
PDF Gossamer Bio (NASDAQ: GOSS 38% terminate development Gossamer's lead candidate, GB001, also an DPS antagonist, is in Phase 2 development for rhinosinusitis and asthma. [Read more]